We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
Read MoreHide Full Article
The market has enjoyed a fantastic run in 2024, building nicely on last year’s gains. Up 8% YTD, the S&P 500’s strong performance has been aided significantly by large-cap technology, with others also joining the party.
However, the performance has been weighed down by a few S&P 500 members, including Tesla (TSLA - Free Report) , Humana (HUM - Free Report) , and Boeing (BA - Free Report) . All three of these stocks have negatively impacted performance, with shares of each in the red in 2024.
It raises a valid question – is this a buying opportunity, or is there more weakness ahead? Let’s take a closer look at each.
Tesla
Down 34% in 2024, Tesla shares have had a bumpy road, with the latest set of quarterly results causing selling pressure post-earnings. Lower margins, hybrid momentum, and competition in China have all been thorns in the company's side.
Image Source: Zacks Investment Research
Analysts’ earnings estimate revisions have reflected the headwinds faced, as shown below.
Image Source: Zacks Investment Research
Tesla’s growth is forecasted to stall slightly in its current year (FY24), with consensus estimates alluding to -2.0% lower earnings on +15% higher sales. Growth resumes in FY25, as expectations presently suggest a +31% pop in earnings on +18.6% higher revenues.
The stock remains a prime consideration for those bullish on the long-term EV picture, but analysts’ recent revisions reflect a cloudy near-term outlook.
Humana
Down 24% year-to-date, Humana shares also saw selling pressure following its latest set of quarterly results. Concerning headline figures in the release, Humana fell short of the Zacks Consensus EPS estimate by 57% and posted a modest 1.4% revenue beat.
Image Source: Zacks Investment Research
The profitability picture throughout the period was hampered by an additional increase in Medicare Advantage medical cost trends, causing the company to give ‘soft’ initial guidance for its FY24. Analysts have slashed their earnings estimates, landing the stock into an unfavorable Zacks Rank #5 (Strong Sell).
Until the company’s earnings picture begins shifting favorably, investors seeking exposure should target stocks in the same industry with favorable Zacks Ranks, such as Cigna Group (CI - Free Report) . Cigna is currently a Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
Boeing
Down 30%, Boeing shares have been impacted negatively by consistent news of maintenance issues found within aircraft in 2024. Just on Monday, it was reported that one of its planes suddenly plunged mid-flight due to an issue in the cockpit.
Image Source: Zacks Investment Research
Analysts have fully taken note of the issues, cutting their earnings expectations significantly across the board. The safety issues are expected to impact the company in a big way, with it grounding the 737 Max in January.
Image Source: Zacks Investment Research
The stock is currently a Zacks Rank #4 (Sell). For those seeking exposure to the Zacks Aerospace & Defense industry, Textron (TXT - Free Report) , a current Zacks Rank #1 (Strong Buy), would be a wiser option for the near-term.
Bottom Line
All three of the above companies – Tesla (TSLA - Free Report) , Humana (HUM - Free Report) , and Boeing (BA - Free Report) – have weighed heavily on the S&P 500’s performance in 2024.
But is it a buying opportunity? Concerning Tesla, the stock remains a great long-term pick for EV exposure, but near-term revisions remain cloudy.
The story is primarily the same regarding Humana and Boeing, with each suffering from negative earnings estimate revisions and carrying unfavorable Zacks Ranks.
A better idea would be to target stocks with a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy), as these stocks have the positive revisions needed to climb higher.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
The market has enjoyed a fantastic run in 2024, building nicely on last year’s gains. Up 8% YTD, the S&P 500’s strong performance has been aided significantly by large-cap technology, with others also joining the party.
However, the performance has been weighed down by a few S&P 500 members, including Tesla (TSLA - Free Report) , Humana (HUM - Free Report) , and Boeing (BA - Free Report) . All three of these stocks have negatively impacted performance, with shares of each in the red in 2024.
It raises a valid question – is this a buying opportunity, or is there more weakness ahead? Let’s take a closer look at each.
Tesla
Down 34% in 2024, Tesla shares have had a bumpy road, with the latest set of quarterly results causing selling pressure post-earnings. Lower margins, hybrid momentum, and competition in China have all been thorns in the company's side.
Image Source: Zacks Investment Research
Analysts’ earnings estimate revisions have reflected the headwinds faced, as shown below.
Image Source: Zacks Investment Research
Tesla’s growth is forecasted to stall slightly in its current year (FY24), with consensus estimates alluding to -2.0% lower earnings on +15% higher sales. Growth resumes in FY25, as expectations presently suggest a +31% pop in earnings on +18.6% higher revenues.
The stock remains a prime consideration for those bullish on the long-term EV picture, but analysts’ recent revisions reflect a cloudy near-term outlook.
Humana
Down 24% year-to-date, Humana shares also saw selling pressure following its latest set of quarterly results. Concerning headline figures in the release, Humana fell short of the Zacks Consensus EPS estimate by 57% and posted a modest 1.4% revenue beat.
Image Source: Zacks Investment Research
The profitability picture throughout the period was hampered by an additional increase in Medicare Advantage medical cost trends, causing the company to give ‘soft’ initial guidance for its FY24. Analysts have slashed their earnings estimates, landing the stock into an unfavorable Zacks Rank #5 (Strong Sell).
Until the company’s earnings picture begins shifting favorably, investors seeking exposure should target stocks in the same industry with favorable Zacks Ranks, such as Cigna Group (CI - Free Report) . Cigna is currently a Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
Boeing
Down 30%, Boeing shares have been impacted negatively by consistent news of maintenance issues found within aircraft in 2024. Just on Monday, it was reported that one of its planes suddenly plunged mid-flight due to an issue in the cockpit.
Image Source: Zacks Investment Research
Analysts have fully taken note of the issues, cutting their earnings expectations significantly across the board. The safety issues are expected to impact the company in a big way, with it grounding the 737 Max in January.
Image Source: Zacks Investment Research
The stock is currently a Zacks Rank #4 (Sell). For those seeking exposure to the Zacks Aerospace & Defense industry, Textron (TXT - Free Report) , a current Zacks Rank #1 (Strong Buy), would be a wiser option for the near-term.
Bottom Line
All three of the above companies – Tesla (TSLA - Free Report) , Humana (HUM - Free Report) , and Boeing (BA - Free Report) – have weighed heavily on the S&P 500’s performance in 2024.
But is it a buying opportunity? Concerning Tesla, the stock remains a great long-term pick for EV exposure, but near-term revisions remain cloudy.
The story is primarily the same regarding Humana and Boeing, with each suffering from negative earnings estimate revisions and carrying unfavorable Zacks Ranks.
A better idea would be to target stocks with a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy), as these stocks have the positive revisions needed to climb higher.